Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

It would not be possible for Black people to be celebrated the way we are today without those who paved the way before us, whether they’re musicians or athletes. Last year, we lost so many ...